Immune Modulation by TLR Agonists and Anti-inflammatory Drugs
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization : University of KwaZulu-Natal
Other organizations : Africa Health Research Institute, Max Planck Institute for Infection Biology, University of Manitoba, Columbia University, University of Cape Town
Variable analysis
- LPS (TLR4)
- R848 (TLR7/8)
- Pam3CSK4 (TLR1/2)
- Measured outcomes
- Final concentration of 2 µg/mL for TLR agonists
- Final concentration of 1 µg/mL for IBF and BMS
- Positive controls not explicitly mentioned
- Negative controls not explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!